

# Noor A Lokman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3387498/publications.pdf>

Version: 2024-02-01

33  
papers

1,333  
citations

393982

19  
h-index

433756

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2568  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chick Chorioallantoic Membrane (CAM) Assay as an In Vivo Model to Study the Effect of Newly Identified Molecules on Ovarian Cancer Invasion and Metastasis. <i>International Journal of Molecular Sciences</i> , 2012, 13, 9959-9970.	1.8	286
2	The Role of Annexin A2 in Tumorigenesis and Cancer Progression. <i>Cancer Microenvironment</i> , 2011, 4, 199-208.	3.1	197
3	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , 2017, 77, 1021-1034.	0.4	94
4	Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. <i>BMC Cancer</i> , 2013, 13, 476.	1.1	66
5	Transforming growth factor- $\beta$ -induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. <i>International Journal of Cancer</i> , 2011, 128, 1570-1584.	2.3	65
6	Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. <i>Oncotarget</i> , 2013, 4, 1199-1211.	0.8	58
7	Differing Roles of Hyaluronan Molecular Weight on Cancer Cell Behavior and Chemotherapy Resistance. <i>Cancers</i> , 2018, 10, 482.	1.7	54
8	Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 441-455.	1.7	50
9	Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance. <i>Oncotarget</i> , 2017, 8, 17819-17832.	0.8	44
10	Targeting CDK9 for treatment of colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2178-2193.	2.1	39
11	Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. <i>Translational Research</i> , 2016, 171, 83-95.e2.	2.2	37
12	Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer. <i>Oncogene</i> , 2017, 36, 4469-4480.	2.6	32
13	S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4122.	1.8	32
14	Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics. <i>Cancer Letters</i> , 2018, 421, 51-58.	3.2	31
15	CIB2 Negatively Regulates Oncogenic Signaling in Ovarian Cancer via Sphingosine Kinase 1. <i>Cancer Research</i> , 2017, 77, 4823-4834.	0.4	29
16	4-Methylumbelliferone Inhibits Cancer Stem Cell Activation and Overcomes Chemoresistance in Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1187.	1.7	29
17	Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 10.	3.5	26
18	Lymph node metastasis of primary endometrial cancers: Associated proteins revealed by MALDI imaging. <i>Proteomics</i> , 2016, 16, 1793-1801.	1.3	25

#	ARTICLE	IF	CITATIONS
19	WOMEN IN CANCER THEMATIC REVIEW: Ovarian cancerâ€“peritoneal cell interactions promote extracellular matrix processing. <i>Endocrine-Related Cancer</i> , 2016, 23, T155-T168.	1.6	21
20	Mass Spectrometry Analyses of Multicellular Tumor Spheroids. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1700124.	0.8	20
21	Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for Monitoring of Drug Response in Primary Cancer Spheroids. <i>Proteomics</i> , 2019, 19, 1900146.	1.3	13
22	MALDI Mass Spectrometry Imaging Reveals Decreased CK5 Levels in Vulvar Squamous Cell Carcinomas Compared to the Precursor Lesion Differentiated Vulvar Intraepithelial Neoplasia. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1088.	1.8	12
23	Reduced Gonadotrophin Receptor Expression Is Associated with a More Aggressive Ovarian Cancer Phenotype. <i>International Journal of Molecular Sciences</i> , 2021, 22, 71.	1.8	12
24	Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2019, 39, 2475-2482.	0.5	9
25	A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 827-838.	0.6	9
26	A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer. <i>Cancers</i> , 2021, 13, 4.	1.7	9
27	Novel IEF Peptide Fractionation Method Reveals a Detailed Profile of N-Terminal Acetylation in Chemotherapy-Responsive and -Resistant Ovarian Cancer Cells. <i>Journal of Proteome Research</i> , 2016, 15, 4073-4081.	1.8	7
28	Ovarian Blood Sampling Identifies Junction Plakoglobin as a Novel Biomarker of Early Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1767.	1.3	7
29	ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome. , 2021, 4, 485-502.		6
30	Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. <i>Diagnostics</i> , 2021, 11, 69.	1.3	5
31	Chemo-resistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations. <i>Cancers</i> , 2022, 14, 2763.	1.7	4
32	Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10844.	1.8	3
33	Chick chorioallantoic membrane assay: a 3D animal model for cancer invasion and metastasis. , 2020, , 221-231.		2